Needham Maintains Taysha Gene Therapies (TSHA) Buy Recommendation
Fintel reports that on August 15, 2023, Needham maintained coverage of Taysha Gene Therapies (NASDAQ:TSHA) with a Buy recommendation.
Analyst Price Forecast Suggests 140.18% Upside
As of August 2, 2023, the average one-year price target for Taysha Gene Therapies is 5.24. The forecasts range from a low of 0.71 to a high of $13.65. The average price target represents an increase of 140.18% from its latest reported closing price of 2.18.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Taysha Gene Therapies is 1MM, a decrease of 93.54%. The projected annual non-GAAP EPS is -1.97.
What is the Fund Sentiment?
There are 69 funds or institutions reporting positions in Taysha Gene Therapies. This is a decrease of 15 owner(s) or 17.86% in the last quarter. Average portfolio weight of all funds dedicated to TSHA is 0.01%, a decrease of 4.40%. Total shares owned by institutions decreased in the last three months by 17.87% to 14,287K shares. The put/call ratio of TSHA is 0.12, indicating a bullish outlook.
What are Other Shareholders Doing?
Tybourne Capital Management holds 1,500K shares representing 2.34% ownership of the company. No change in the last quarter.
Artal Group holds 1,441K shares representing 2.25% ownership of the company. No change in the last quarter.
Nantahala Capital Management holds 1,251K shares representing 1.95% ownership of the company. In it’s prior filing, the firm reported owning 1,722K shares, representing a decrease of 37.67%. The firm decreased its portfolio allocation in TSHA by 22.73% over the last quarter.
Laurion Capital Management holds 1,172K shares representing 1.83% ownership of the company. No change in the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 1,158K shares representing 1.80% ownership of the company. No change in the last quarter.
Taysha Gene Therapies Background Information
(This description is provided by the company.)
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined its team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, Taysha Gene Therapies leverages its fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives.
Additional reading:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Summarize this content to 100 words
Fintel reports that on August 15, 2023, Needham maintained coverage of Taysha Gene Therapies (NASDAQ:TSHA) with a Buy recommendation. Analyst Price Forecast Suggests 140.18% Upside As of August 2, 2023, the average one-year price target for Taysha Gene Therapies is 5.24. The forecasts range from a low of 0.71 to a high of $13.65. The average price target represents an increase of 140.18% from its latest reported closing price of 2.18.
See our leaderboard of companies with the largest price target upside. The projected annual revenue for Taysha Gene Therapies is 1MM, a decrease of 93.54%. The projected annual non-GAAP EPS is -1.97. What is the Fund Sentiment? There are 69 funds or institutions reporting positions in Taysha Gene Therapies. This is a decrease of 15 owner(s) or 17.86% in the last quarter. Average portfolio weight of all funds dedicated to TSHA is 0.01%, a decrease of 4.40%. Total shares owned by institutions decreased in the last three months by 17.87% to 14,287K shares. The put/call ratio of TSHA is 0.12, indicating a bullish outlook. What are Other Shareholders Doing? Tybourne Capital Management holds 1,500K shares representing 2.34% ownership of the company. No change in the last quarter. Artal Group holds 1,441K shares representing 2.25% ownership of the company. No change in the last quarter.
Nantahala Capital Management holds 1,251K shares representing 1.95% ownership of the company. In it’s prior filing, the firm reported owning 1,722K shares, representing a decrease of 37.67%. The firm decreased its portfolio allocation in TSHA by 22.73% over the last quarter. Laurion Capital Management holds 1,172K shares representing 1.83% ownership of the company. No change in the last quarter. VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 1,158K shares representing 1.80% ownership of the company. No change in the last quarter. Taysha Gene Therapies Background Information(This description is provided by the company.) Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined its team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, Taysha Gene Therapies leverages its fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives.
Additional reading: This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
https://www.nasdaq.com/articles/needham-maintains-taysha-gene-therapies-tsha-buy-recommendation Needham Maintains Taysha Gene Therapies (TSHA) Buy Recommendation